Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidirOct 5, 2026

Using GLP-1 and Dual GIP/GLP-1 Medicines for Obesity: Practical Advice for Doctors

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 6, 2026

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may lead to clinically meaningful weight loss and improved metabolic health markers.

Obesity is linked to significant cardiometabolic health risks.
GLP-1 RAs and newer GIP/GLP-1 RAs are effective for treating obesity.
Effective use of these medications involves careful patient selection and management.
Key components of treatment include counseling, dose titration, and long-term follow-up.
Practical differences between semaglutide and tirzepatide are outlined for prescribing.
A step-by-step framework is provided for clinicians to enhance treatment efficacy.

Simplified

Obesity is a chronic and frequently relapsing disease associated with a substantial burden of cardiometabolic morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), along with newer dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (GIP/GLP-1 RAs), have emerged as effective pharmacological treatments for obesity, producing clinically meaningful weight loss and improving several markers of metabolic health. However, the effective use of these agents requires more than prescribing alone: patients must be selected appropriately, contraindications must be assessed, counseling must be provided, doses must be titrated gradually, side effects must be managed, and long-term follow-up must be maintained. This practical guideline offers clinicians a step-by-step framework, from determining eligibility and performing baseline evaluation to initiating therapy, monitoring response, managing commonly encountered side effects, and maintaining weight loss in the months and years that follow. Practical differences between semaglutide and tirzepatide are also summarized to support day-to-day prescribing decisions.

Using GLP-1 and Dual GIP/GLP-1 Medicines for Obesity: Practical Advice for Doctors

Abstract

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief